Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

34.87USD
21 Aug 2019
Change (% chg)

$0.26 (+0.75%)
Prev Close
$34.61
Open
$34.95
Day's High
$35.12
Day's Low
$34.83
Volume
4,814,647
Avg. Vol
6,679,339
52-wk High
$46.46
52-wk Low
$33.97

Select another date:

Wed, Aug 21 2019

Photo

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

Pfizer invests $500 million in expanding gene therapy facility

Aug 21 Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

UPDATE 2-J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON, July 29 The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV , a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar. | Video

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

UPDATE 2-Mylan deal puts future of its beleaguered EpiPen in spotlight

July 29 Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Deals of the day-Mergers and acquisitions

July 30 The following bids, mergers, acquisitions and disposals were reported by 2025 GMT on Monday:

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV , a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar. | Video

Select another date: